Mazdutide Weight Loss: What the Trials Show So Far
Mazdutide is still being studied for weight loss. Among approved GLP-1s, the top average loss in a main trial is 20.9%, on tirzepatide 15 mg weekly in SURMOUNT-1.
Weight loss and half-life, in brief
A dose’s half-life in days is the time your body needs to remove half of it. This figure comes from section 12.3 of the FDA label.
As a percent of body weight. Trials, doses and lengths vary, so check each one against the placebo listed on its page.
Approved options and what their trials showed
At present, Mazdutide can only be prescribed as part of a trial. What these approved medicines can do, judged by their main weight trials:
| Trial | Dose group | Average weight lost | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg weekly | 14.9% | 2.4% | 68 | Adults with obesity or overweight, without diabetes |
| OASIS 4 | Wegovy pill 25 mg daily | 13.6% | 2.4% | 64 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-1 | Tirzepatide 15 mg weekly | 20.9% | 3.1% | 72 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-2 | Tirzepatide 15 mg weekly | 14.7% | 3.2% | 72 | Adults who have obesity or overweight plus type 2 diabetes |
| SCALE Obesity and Prediabetes | Liraglutide 3.0 mg daily | 7.4% | 3% | 56 | Adults who have obesity or overweight plus type 2 diabetes |
| ATTAIN-1 | Foundayo 17.2 mg daily | 11.1% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-2 | Foundayo 17.2 mg daily | 9.6% | 2.5% | 72 | Adults who have obesity or overweight plus type 2 diabetes |
| STEP 2 | Semaglutide 2.4 mg weekly | 9.6% | 3.4% | 68 | Adults who have obesity or overweight plus type 2 diabetes |
Sources: STEP 1 (FDA label (DailyMed)), SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-2 (PubMed), SCALE Obesity and Prediabetes (FDA label (DailyMed)), ATTAIN-1 (FDA label (DailyMed)), STEP 2 (PubMed).